A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study

David S Ettinger, R. Day, J. A. Ferraro, J. C. Ruckdeschel, J. E. Woll, R. H. Creech, S. E. Vogl

Research output: Contribution to journalArticle

Abstract

Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

Original languageEnglish (US)
Pages (from-to)167-170
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume6
Issue number2
StatePublished - 1983

Fingerprint

Zinostatin
Amsacrine
Bronchogenic Carcinoma
Fever
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study. / Ettinger, David S; Day, R.; Ferraro, J. A.; Ruckdeschel, J. C.; Woll, J. E.; Creech, R. H.; Vogl, S. E.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 6, No. 2, 1983, p. 167-170.

Research output: Contribution to journalArticle

@article{9815ed4a26c74231babfe58e8cd4008f,
title = "A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study",
abstract = "Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5{\%}) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.",
author = "Ettinger, {David S} and R. Day and Ferraro, {J. A.} and Ruckdeschel, {J. C.} and Woll, {J. E.} and Creech, {R. H.} and Vogl, {S. E.}",
year = "1983",
language = "English (US)",
volume = "6",
pages = "167--170",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell bronchogenic carcinoma. An Eastern Cooperative Group Study

AU - Ettinger, David S

AU - Day, R.

AU - Ferraro, J. A.

AU - Ruckdeschel, J. C.

AU - Woll, J. E.

AU - Creech, R. H.

AU - Vogl, S. E.

PY - 1983

Y1 - 1983

N2 - Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

AB - Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily x 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020535590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020535590&partnerID=8YFLogxK

M3 - Article

C2 - 6299093

AN - SCOPUS:0020535590

VL - 6

SP - 167

EP - 170

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -